Nivolumab produces long-lasting responses in patients with stage IV melanoma: Dr Mario Sznol
Nivolumab produces long-lasting responses in patients with stage IV melanoma: Dr Mario Sznol
Dr Mario Sznol talks to ecancer at ASCO 2013 about long-term follow-up results from an expanded phase I study examining ... Read more
13 Jun 2013
•
ASCO 2013 highlights
ASCO 2013 highlights
Dr Swchwartz gives ecancertv his ASCO 2013 highlights. He covers the latest promising news in melanoma and comments on t... Read more
13 Jun 2013
•
Similar Podcasts
2014 ASCO Annual Meeting
2013 NMC Summer Conference
Energy - Delivering a Secure & Sustainable Supply for the Future
The Amputee Guy
Das politische System Deutschlands_2012
Bienvenida de cursos 2016-2017
2015 Abedian School of Architecture Lecture Series
América Latina 1960-2013
A Day In The Life w/ Kedric D. Vance, Sr.
The Artists Project
The Fat chronicles
WREC 600 AM & 92.1 FM FERGUSON
Artificial Intelligence
Dr LaMort
The Cryptoshow - blockchain, cryptocurrencies, Bitcoin and decentralization simply explained
Affects of The Cancer Genome Atlas
Affects of The Cancer Genome Atlas
Dr Matthew Ellis talks to ecancer at ASCO 2013 about the affects of The Cancer Genome Atlas on research, treatment and n... Read more
13 Jun 2013
•
7mins
Phase I study measures effect of ipilimumab and nivolumab combination in melanoma patients: Prof Jedd Wolchok
Phase I study measures effect of ipilimumab and nivolumab combination in melanoma patients: Prof Jedd Wolchok
Prof Jedd Wolchok talks to ecancer at the 2013 ASCO Annual Meeting about a phase I study that involved the drug combinat... Read more
13 Jun 2013
•
Most Popular Podcasts
The Joe Rogan Experience
TED Talks Daily
The Tim Ferriss Show
The Daily
Stuff You Should Know
Oprah's SuperSoul Conversations
Armchair Expert with Dax Shepard
Rituximab vedotin in the frontline setting: Dr Stephen Ansell
Rituximab vedotin in the frontline setting: Dr Stephen Ansell
Dr Stephen Ansell talks to ecancer at ASCO 2013 about rituximab vedotin, an anti-CD30 chemotherapy agent, which allows f... Read more
13 Jun 2013
•
Development and clinical trials of Z100: Dr Keiichi Fujiwara
Development and clinical trials of Z100: Dr Keiichi Fujiwara
Dr Keiichi Fujiwara talks to ecancer at ASCO 2013 about the efficacy of Z100, an immunomodulator that has been in develo... Read more
13 Jun 2013
•
5mins
Axillary radiotherapy provides alternative to invasive early stage breast cancer surgery : Dr Emiel J. Rutgers
Axillary radiotherapy provides alternative to invasive early stage breast cancer surgery : Dr Emiel J. Rutgers
Dr Emiel J. Rutgers talks to ecancer at ASCO 2013 on a European phase III clinical trial called AMAROS.The study found t... Read more
13 Jun 2013
•
AMAROS trial: radiotherapy versus lymph node dissection in breast cancer: Dr Robert Mansel
AMAROS trial: radiotherapy versus lymph node dissection in breast cancer: Dr Robert Mansel
Dr Robert Mansel talks to ecancer at ASCO 2013 about the AMAROS trial which investigated complete axillary lymph node di... Read more
13 Jun 2013
•
4mins
Improving outcomes of childhood neuroblastoma: Dr Garrett Brodeur
Improving outcomes of childhood neuroblastoma: Dr Garrett Brodeur
Dr Garrett Brodeur talks to ecancer at the 2013 ASCO Annual Meeting in Chicago about childhood cancer neuroblastoma, ALK... Read more
13 Jun 2013
•
8mins
Role of microenvironment and stroma in cancer therapy: Dr Stephen Ansell
Role of microenvironment and stroma in cancer therapy: Dr Stephen Ansell
Dr Ansell talks to ecancertv at ASCO 2013 about the tumour microenvironment and stroma and its role in cancer. He covers... Read more
13 Jun 2013
•
2mins
